VIDEO “Do Generic Drugs Get a ‘Free Pass’?”: Second Appearance on The American Law Journal
At the end of April, I appeared on The American Law Journal to discuss generic drug liability with host Christopher Naughton…
Whistleblower Legislation Primer: False Claims Act and qui tam
In a 60-minute webinar Brian J. McCormick and I discussed the process of a whistleblower qui tam claim in depth, from the perspective of the relator, attorneys, investigators, and others.
I’m a partner with Sheller, P.C. who specializes in whistleblower, pharmaceutical, and consumer protection litigation.
Listen to my appearance on “Legally Speaking” Radio, discussing Whistleblowing, qui tam and False Claims Act, pharma product liability, and more. ...
Claudine, Joe Scarborough and Mika Brzezinski at the Committee of Seventy luncheon, Philadelphia, PA
ProPublica Followup: “Double Dose: In Second Case of Flawed Drug Research, FDA Response Was Slow and Secretive”
Double Dose: In Second Case of Flawed Drug Research, FDA Response Was Slow and Secretive by Rob Garver and Charles…
ProPublica: “Five Drugs the FDA Doesn’t Want You to Know Relied on Tainted Data”
by Charles Seife and Rob Garver, Special to ProPublica April 15, 2013 In 2011, the Food and Drug Administration determined…
ProPublica Reports: “FDA Let Drugs Approved on Fraudulent Research Stay on the Market”
FDA Let Drugs Approved on Fraudulent Research Stay on the Market by Rob Garver and Charles Seife, Special to ProPublica,…
